LinkedIn Corp (NYSE:LNKD) was upgraded by stock analysts at Ned Davis Research from a “sell” rating to a “neutral” rating in a report issued on Monday, American Banking News reports. LinkedIn Corp (NYSE:LNKD) net profit margin is -0.60% and weekly performance is 1.53%. On last trading day company shares ended up $145.56. Analysts mean target price for the company is $226.00. LinkedIn Corp (NYSE:LNKD) distance from 50-day simple moving average (SMA50) is -17.62%.
A week after Gawker published an anonymous rant from a Target Corporation (NYSE:TGT) employee that further revealed the extent to which the retailer’s massive data breach has affected both employee and customer morale, the retailer’s Chief Marketing Officer Jeff Jones responded with a LinkedIn post titled “The Truth Hurts.” Target Corporation (NYSE:TGT) shares fell -0.49% in last trading session and ended the day on $59.27. TGT gross Margin is 29.50% and its return on assets is 4.40%.Target Corporation (NYSE:TGT) quarterly performance is 4.87%.
Gross profits of NetEase, Inc. (ADR) (NASDAQ:NTES) one of China’s leading Internet and online game providers, reached 1.7 billion yuan ($275 million) in the first quarter of 2014. NetEase, Inc. (ADR) (NASDAQ:NTES) shares moved down -0.55% in last trading session and was closed at $71.04, while trading in range of $70.00 – $71.88. NetEase, Inc. (ADR) (NASDAQ:NTES) year to date (YTD) performance is -7.79%.
On April 29, 2014, the United States Oil Fund, LP (NYSEARCA:USO) issued its monthly account statement for the month ended March 31, 2014, which is presented in the form of a Statement of Income (Loss) and a Statement of Changes in Net Asset Value, as required pursuant to Rule 4.22 under the Commodity Exchange Act. United States Oil Fund LP (ETF) (NYSEARCA:USO) ended the last trading day at $37.18. Company weekly volatility is calculated as 0.79%. United States Oil Fund LP (ETF) (NYSEARCA:USO) showed a positive weekly performance of 1.58%.
Eisai Co. Ltd. (ADR) (OTCMKTS:ESALY) has exercised its option to jointly develop and commercialize its clinical candidates for Alzheimer’s disease with US biotechnology firm Biogen Idec. The option was included as part of Eisai’s collaboration agreement with Biogen Idec announced in March 2014. Eisai Co., Ltd (ADR) (OTCMKTS:ESALY) ended the last trading day at $39.17.